Search for: "Sanofi Synthelabo"
Results 21 - 40
of 59
Sort by Relevance
|
Sort by Date
24 Sep 2010, 1:15 pm
Sanofi-Synthelabo v. [read post]
24 Sep 2010, 1:06 pm
”Sanofi-Synthelabo v. [read post]
7 Sep 2010, 8:52 am
The Updated Guidelines go through a number of cases, but the take away instructions for Office personnel can perhaps best be summarized in Example 4.18, which discusses Sanofi-Synthelabo v. [read post]
2 Sep 2010, 10:51 am
Sanofi-Synthelabo v. [read post]
Three Strikes, You’re Out!? Apotex’s Latest Attempt to Invalidate the PLAVIX® Patent Denied by USPTO
9 Jul 2010, 3:00 am
Court of Appeals for the Federal Circuit (Sanofi-Synthelabo v. [read post]
3 Feb 2010, 2:00 am
Barr Laboratories, Inc. and Mylan Pharma (Patent Docs) (Patently-O) Omnicef (Cefdinir) – US: CAFC on whether a product-by-process claim is infringed by an identical product made by different process: Abbott Labs v Sandoz (IP Frontline) Pertussis vaccines – UK: EWHC dismisses Medeva appeal against pertussis vaccines SPCs refusal (The SPC Blog) Plavix (Clopidogrel) – Canada: Adding some obvious flexibility: Apotex Inc v Sanofi-Synthelabo Canada Inc (IP Osgoode)… [read post]
30 Nov 2009, 12:00 am
– visual artists will eventually receive small share of resale value of their artworks (1709 Copyright Blog) Canada Patents update – new Practice Notice on Obviousness 2 Nov 2009 – introduces four part test on obviousness following Apotex v Sanofi-Synthelabo (ipblog.ca) Court injects ‘duty of candour’ requirements for patent agents: Lundbeck Canada v Ratiopharm (Pharmacapsules @ Gowlings) Vancouver Olympic Committee unravels Cowichan sweater… [read post]
2 Nov 2009, 1:20 pm
Sanofi-Synthelabo Canada, Inc. [2008 SCC 61] The four-step approach to obviousness adopted by the Court is as follows: (1) (a) Identify the notional "person skilled in the art"; (b) Identify the relevant common general knowledge of that person; (2) Identify the inventive concept of the claim in question or if that cannot readily be done, construe it; (3) Identify what, if any, difference exists between the matter cited as forming part of the "state of the art"… [read post]
29 Oct 2009, 11:11 am
Sanofi-Synthelabo, Inc. [read post]
26 May 2009, 9:54 am
., IVAX Pharmaceuticals, Barr Laboratories, Aventis Pharmaceuticals, Aventis Behring, ZLB Behring, Sanofi-Synthelabo, Forest Laboratories, Forest Pharmaceuticals, Baxter Healthcare Corp. and Baxter International. [read post]
13 May 2009, 11:44 pm
Cir. 2008); see also Sanofi-Synthelabo v. [read post]
23 Mar 2009, 7:34 am
After a detailed analysis of the facts, the court agreed with the district court's analysis that the disclosure of the chemical structure of the compound in the prior art was insufficient to either anticipate or render obvious a claim directed to one of the two enantiomers, given the difficulty and unpredictability in separating enantiomers and the unexpected division of the beneficial and harmful effects between the two enantiomers of this particular compound.More detail of… [read post]
25 Jan 2009, 2:36 pm
The last big pharmaceutical industry acquisition came in August 2004, when Paris-based Sanofi-Synthelabo acquired Aventis SA of Strasburg, France, for $64.4 billion to create Sanofi Aventis SA, France's largest drugmaker. [read post]
24 Dec 2008, 3:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Classen v Biogen (not precedential): Federal Circuit applies Bilski to the life sciences (Holman's Biotech IP Blog) (Inventive Step) (Hal Wegner) (EFF) (Patently-O) (Patent Prospector) (The Fire of Genius) (Patent Baristas) (Managing Intellectual Property) (Patent Docs) (Spicy IP) General India: Investing farmers with IP… [read post]
20 Dec 2008, 3:00 am
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
19 Dec 2008, 1:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Plavix (Clopidogrel) – US: CAFC affirms nonobviousness of Plavix isomer patent: Sanofi-Synthelabo et al v Apotex (Patently-O) (Orange Book Blog) (Patent Prospector) (Law360) (Hal Wegner) (Patent Baristas) (Patent Docs) (Promote the Progress) (GenericsWeb) WHO meeting on pandemic influenza preparedness: last-minute… [read post]
16 Dec 2008, 11:47 pm
Sanofi-Synthelabo v. [read post]
16 Dec 2008, 5:16 am
Sanofi-Synthelabo, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership (collectively, Sanofi) brought suit under 35 U.S.C. [read post]
15 Dec 2008, 9:51 pm
Sanofi-Synthelabo et al. v. [read post]
15 Dec 2008, 2:00 pm
Shortly after the drug hit the market, Sanofi-Synthelabo, which owns the Plavix patent, and Bristol-Myers Squibb, owner of the Plavix marketing rights, sought and obtained an injunction barring sales of the generic. [read post]
